Pfizer
2Q Revenues: $12.7 billion (-54%)
2Q Earnings: $2.3 billion (-77%)
YTD Revenues: $31.0 billion (-42%)
YTD Earnings: $7.9 billion (-56%)
Comments: Primary Care revenues were down 72% to $5.8 billion in the quarter, reflecting an operational decline of $14.7 billion, or 53%, primarily due to the drop in global Paxlovid and Comirnaty revenues. Revenues from Comirnaty and Paxlovid were $1.6 billion, down 82% and 98%, respectively. Recently acquired products, Nurtec ODT/Vydura and Oxbryta, contributed $247 million and $77 million in global revenues.
 
Specialty Care sales were up 12% to $3.65 billion. Global Vyndaqel sales were up 40% to $262 million, driven by continued strong uptake of the transthyretin amyloid cardiomyopathy (ATTR-CM) indication. Inflectra sales were down 46% to $74 million, primarily due to lower net price as a result of unfavorable changes in channel mix.  
 
Oncology revenues were down 3% to $2.96 billion with Ibrance sales down 6% to $1.2 billion driven by lower demand globally due to competition.
 
Pfizer CentreOne revenues were down 4% to $306 million.